 | • レポートコード：MRC2303I0162 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の豚ワクチン市場規模が、予測期間中（2022年-2027年）に年平均5.2%で成長すると予測しています。本書では、豚ワクチンの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（不活化ワクチン、弱毒生ワクチン、組換えワクチン、その他）分析、病型別（豚コレラ、豚パルボウイルス、豚インフルエンザ、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国地域）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Merck & Co., Inc.、Zoetis Services LLC、Ceva、Boehringer Ingelheim International GmbH、Elanco、Biogenesis Bago、KM Biologics、HIPRA、Vaxxinova International BV、Phibro Animal Health Corporationなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の豚ワクチン市場規模：製品別 - 不活化ワクチンの市場規模 - 弱毒生ワクチンの市場規模 - 組換えワクチンの市場規模 - その他の市場規模 ・世界の豚ワクチン市場規模：病型別 - 豚コレラの市場規模 - 豚パルボウイルスの市場規模 - 豚インフルエンザの市場規模 - その他の市場規模 ・世界の豚ワクチン市場規模：地域別 - 北米の豚ワクチン市場規模 アメリカの豚ワクチン市場規模 カナダの豚ワクチン市場規模 メキシコの豚ワクチン市場規模 … - ヨーロッパの豚ワクチン市場規模 ドイツの豚ワクチン市場規模 イギリスの豚ワクチン市場規模 フランスの豚ワクチン市場規模 … - アジア太平洋の豚ワクチン市場規模 中国の豚ワクチン市場規模 インドの豚ワクチン市場規模 日本の豚ワクチン市場規模 … - その他地域の豚ワクチン市場規模 ・競争状況 ・市場機会・将来の動向 |
The swine vaccines market is expected to register a CAGR of 5.2% over the forecast period, 2022-2027.
The COVID-19 pandemic has had a substantial impact on the swine vaccines market. The animal health industry witnessed an adverse impact owing to the outbreak of COVID-19. Delays in the delivery of the active ingredients and raw materials and capacity constraints were some of the major concerns that restrained the market’s growth during the pandemic. However, an increase in R&D investments to develop advanced products for better treatment and diagnosis during a pandemic can be considered one of the driving factors for the swine vaccines market. For instance, in May 2020, Indian Immunologicals Limited (IIL) launched a Classical Swine Fever (CSF) vaccine under the brand name “Raksha Class”. This cell culture technology-based vaccine was developed in collaboration with the Indian Veterinary Research Institute (IVRI). Such innovation helped to regain market pace over the pandemic phase.
Furthermore, the increasing cases of swine fever in developing countries is also one of the major factors propelling the market’s growth over the forecast period. For instance, as per the report published by the Foundation for Food & Agriculture Research in April 2022, African Swine Fever (ASF) has emerged as one of the highly contagious viruses that cause 100% mortality in swine. As of now, there is no commercially available vaccine to treat the disease. Therefore, in order to combat the disease, the Foundation for Food & Agricultural Research granted USD 145,000 to Genvax Technologies for developing a self-amplifying messenger RNA (saRNA) vaccine for African Swine Fever in association with the United States Department of Agriculture-Agricultural Research Services-Plum Island Animal Disease Center (USDA-ARS-PIADC). African Swine Fever has been detected in many countries until now, except in the United States. In addition, government initiatives toward swine flu management are also one of the major factors driving the market growth. The outbreak of the African Swine Flu (ASF) in many countries, such as China, India, Malaysia, Indonesia, and others, has led to the introduction of certain initiatives by the government. For instance, as per the report published by the Food and Agriculture Organization of the United Nations in April 2021, the Ministry of Agriculture and Rural Affairs (MARA) published a “Work Plan for Regional Prevention and Control of African Swine Fever and Other Major Animal Diseases (Trial)” for better management and control of animal diseases. Similarly, as per the journal published by Phys.org in June 2022, Vietnamese researchers developed a vaccine against African swine fever for pigs in collaboration with the United States.
Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the high cost of maintaining and handling storage conditions is likely to impede the market’s growth.
Swine Vaccines Market Trends
Inactivated Vaccines Segment is Expected to Witness Growth Over the Forecast Period
By product, the inactivated vaccines segment is likely to register significant growth throughout the forecast period. Inactivated vaccines may contain antigens of organisms that are chemically synthesized or the whole organism in an inactivated state. The immunity ratio in inactivated vaccines can be enhanced by adding adjuvants or substances such as certain types of oil or aluminum hydroxide. These vaccines also contain toxins that are usually modified to stimulate an immune response in swine. CIRCOVAC, PARVOVAX, and PROGRESSIS from Ceva are some of the examples of inactivated vaccines against swine flu available on the market. Various research studies related to inactivated vaccines are in the pipeline to check their effectiveness against various swine diseases. For instance, as per the data published by the National Library of Medicine in March 2022, a research study on inactivated Senecavirus A vaccine is in the pipeline to check its efficacy on Senecavirus A (SVA). Senecavirus A, also known as Senecavirus A, is responsible for causing vesicular disease in swine. Hence, such research and development activities are anticipated to boost the segment’s growth over the forecast period.
Additionally, the several advantages of inactivated vaccines over other vaccines are one of the major factors driving the segment’s growth. Inactivated vaccines allow a higher rate of protection against diseases than live attenuated vaccines. In addition, the chance of reversion in inactivated vaccines is comparatively less than in other types. Furthermore, inactivated vaccines can be recommended for those having immunity concerns. The ease of transportation of inactivated vaccines is quite high compared to other vaccines, as these vaccines can be freeze-dried. In terms of storage purposes and shipping, inactivated vaccines are much more convenient, which also becomes an advantage for manufacturers.
Therefore, the inactivated vaccines segment is expected to witness significant growth over the forecast period due to the abovementioned factors.
North America is Expected to Dominate the Swine Vaccines Market
North America is expected to dominate the market owing to factors such as an increasing number of diseases and rising R&D expenditure to develop advanced products in the region. An increase in the usage of swine vaccines owing to the highly organized farming structures in the United States is among the key factors that contribute to the growth of the studied market in North America. For instance, in March 2022, the USDA’s National Institute of Food and Agriculture (NIFA) granted USD 642,000 to Cornell University to develop swine influenza vaccines. Therefore, such initiatives are anticipated to promote market growth in this region.
Moreover, key product launches, high concentration of market players, or manufacturers’ presence in the United States are some of the other factors driving the growth of the swine vaccine market in the country. For instance, in September 2020, Pharmgate Animal Health launched PRRSGard, a modified-live vaccine in the United States. It is a 1.0 milliliter single-dose recombinant chimeric vaccine recommended for porcine respiratory and reproductive syndrome. These continuous product launches in the region are anticipated to drive the growth of the market in the country.
Therefore, owing to the aforementioned factors, the growth of the studied market is anticipated in the North American region.
Swine Vaccines Market Competitor Analysis
The swine vaccines market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold the market shares and are well known, including Merck Animal Health, Zoetis, Ceva Sante Animale, Boehringer Ingelheim GmbH, Elanco, Biogenesis Bagó, KM Biologics, HIPRA, and Phibro Animal Health, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Government Initiatives toward Swine Flu Management and Increasing Awareness about Influenza A
4.2.2 Increase In Research and Development Expenditure Toward Vaccine Innovation
4.3 Market Restraints
4.3.1 High Expenses of Maintaining and Handling Storage Conditions along with Chance of Reverse Reaction from Vaccines
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Inactivated Vaccines
5.1.2 Attenuated Live Vaccines
5.1.3 Recombinant Vaccines
5.1.4 Others
5.2 By Disease Type
5.2.1 Classical Swine Fever
5.2.2 Porcine Parvovirus
5.2.3 Swine Influenza
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of the World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co., Inc.
6.1.2 Zoetis Services LLC
6.1.3 Ceva
6.1.4 Boehringer Ingelheim International GmbH
6.1.5 Elanco
6.1.6 Biogenesis Bago
6.1.7 KM Biologics
6.1.8 HIPRA
6.1.9 Vaxxinova International BV
6.1.10 Phibro Animal Health Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS